surpass cvot tirzepatide results Can Dual Incretin Receptor Agonists Exert Better Cardiovascular Protection than Selective GLP-1 Receptor Agonists? Highlights from SURPASS-CVOT | Diabetes Therapy surpass cvot tirzepatide results Comparison

The best maintenance dose of ipamorelin depends heavily on research objectives

Go to StopTheBOP to learn more about this issue

The results were consistent with the overall SELECT trial findings and showed a numerically larger risk reduction in the perimenopausal women (42% lower risk compared to placebo) compared to the postmenopausal women (13% lower risk compared to placebo), although the difference between the groups was not statistically significant

Gustav Lo | RegenCen For years, GLP-1 medications like tirzepatide and semaglutide have been seen exclusively as weight-loss drugs

Traveling across time zones: the special case Crossing multiple time zones creates a unique timing challenge

doi: 10.1016/j.vetpar.2023.110011 32 Witko-SarsatVNguyen-KhoaTJungersPDrekeTBDescamps-LatschaB